Entero Therapeutics Inc. is a biopharmaceutical company focused on developing innovative therapies for gastrointestinal disorders and related health conditions
The company is dedicated to advancing its proprietary drug delivery technologies and treatment strategies that target the gastrointestinal tract, aiming to improve the lives of patients with challenging medical issues. Through rigorous research and development, Entero is committed to addressing unmet medical needs in the field of digestive health and enhancing the effectiveness of existing therapies.
NEW YORK, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
BALA CYNWYD, Pa., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
BALA CYNWYD, Pa., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
NEW YORK, Nov. 16, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Entero Therapeutics, Inc. (NasdaqCM: ENTO) and Journey Therapeutics, Inc. Pursuant to the terms of the agreement, upon completion of the proposed transaction, Journey shareholders will acquire 99% of the equity of Entero. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger is fair to Entero shareholders.
NEW YORK, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Entero Therapeutics, Inc. (NASDAQENTO) and Journey Therapeutics, Inc. is fair to Entero shareholders. Upon closing of the proposed transaction, Journey shareholders will acquire 99% of the equity of Entero.
BALA CYNWYD, Pa., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
